METFORMIN DEMONSTRATES EFFICACY IN OVERCOMING CISPLATIN RESISTANCE WITHIN TRIPLE-NEGATIVE BREAST CANCER CELLS BY SPECIFICALLY TARGETING RAD51

Breast cancer, the most common disease in women worldwide, poses several difficulties, especially when it comes to triple-negative breast cancer (TNBC), which is defined by the lack of certain receptors. The RAD51 gene family, vital for DNA maintenance, is implicated in cancer, including TNBC. Cisplatin, a potent anticancer drug, often loses effectiveness due to resistance mechanisms. Metformin, a diabetes medication, has shown promise in breast cancer treatment. This study investigates their combined impact on TNBC

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2024-09-18
DOI
https://doi.org/10.5281/zenodo.13784591
Primary Topic
Metabolism, Diabetes, and Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

METFORMIN DEMONSTRATES EFFICACY IN OVERCOMING CISPLATIN RESISTANCE WITHIN TRIPLE-NEGATIVE BREAST CANCER CELLS BY SPECIFICALLY TARGETING RAD51

Zenodo (CERN European Organization for Nuclear Research)
Metabolism, Diabetes, and Cancer
article

METFORMIN DEMONSTRATES EFFICACY IN OVERCOMING CISPLATIN RESISTANCE WITHIN TRIPLE-NEGATIVE BREAST CANCER CELLS BY SPECIFICALLY TARGETING RAD51

article en

Abstract

Breast cancer, the most common disease in women worldwide, poses several difficulties, especially when it comes to triple-negative breast cancer (TNBC), which is defined by the lack of certain receptors. The RAD51 gene family, vital for DNA maintenance, is implicated in cancer, including TNBC. Cisplatin, a potent anticancer drug, often loses effectiveness due to resistance mechanisms. Metformin, a diabetes medication, has shown promise in breast cancer treatment. This study investigates their combined impact on TNBC

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 58%
Metabolism, Diabetes, and Cancer
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

METFORMIN DEMONSTRATES EFFICACY IN OVERCOMING CISPLATIN RESISTANCE WITHIN TRIPLE-NEGATIVE BREAST CANCER CELLS BY SPECIFICALLY TARGETING RAD51 · Zenodo (CERN European Organization for Nuclear Research) (2024) | TGRS Research Map | TGRS